ID | 114819 |
Author |
Kato, Yoshikane
Kanaiso Hospital
Matsuzaki, Sayuri
Kanaiso Hospital
Waka, Shinnichi
Kanaiso Hospital
|
Keywords | chronic kidney disease (CKD)
Metformin
Canagliflozin
erythropoiesis stimulating agent (ESA)
hypoxia-inducible factor (HIF)
|
Content Type |
Journal Article
|
Description | The authors and colleagues have been involved in Non-Communicable Diseases (NCDs), especially including diabetes, chronic kidney disease (CKD) and hemodialysis. Some topics are described as possible therapy for CKD. (i) Metformin has inhibitory effect on cardiovascular events, and has an evidence for safe administration in mild to moderate renal impairment. (ii) Canagliflozin reduced moderately cardiovascular and renal outcomes across the primary and secondary prevention groups, from mega studies of CANVAS and CREDENCE. (iii) erythropoiesis stimulating agent (ESA) has been effective for improving anemia in HD for years. Some hypoxia-inducible factor (HIF) seems to be applied for clinical practice soon.
|
Journal Title |
Pharmacy and Pharmacology International Journal
|
ISSN | 23736367
|
Publisher | MedCrave Publishing
|
Volume | 8
|
Issue | 2
|
Start Page | 87
|
End Page | 89
|
Published Date | 2020-04-15
|
Rights | ©2020 Kato et al. This is an open access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and build upon your work non-commercially.
|
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Medical Sciences
|